Wednesday, 17 Oct 2018

You are here

Ultrasound Tenosynovitis Predicts RA Development

Musculoskeletal ultrasound (US) has become a more widely used tool in rheumatology clinical practice.  This study of early inflammatory arthritis patients shows that US-defined digit flexor tenosynovitis (TS) was more predictive of subsequent rheumatoid arthritis (RA) than findings of ACPA positivity or US-defined joint synovitis.

A cohort of 107 early arthritis patients underwent baseline clinical, laboratory and US assessment of 19 bilateral joint sites and 16 bilateral tendon compartments. Ultimate outcomes were determined 18 months later using the 2010 ACR/EULAR classification criteria for RA.

A total of 46/107 patients developed persistent RA, 17 patients developed non-RA persistent disease and 44 patients had resolved their disease at follow-up.

US-defined TS was more likely in RA, but was seen in all groups studied (RA 85%, non-RA persistent disease 71% and resolving 70%). RA patients were more likely to have grey scalle (GS) and power doppler (PD) changes at PIP 1–5, MCP 1–5, wrist, elbow, MTP 3 and MTP 5 joints. In addition, RA patients were more likely to have MTP 2 PD changes, but not GS changes alone, compared with patients with resolving arthritis.

On multi-variate analysis, US-defined digit flexor TS provided independent predictive data over and above the presence of ACPA and US-defined joint synovitis.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Predictive Risk Factors for Uveitis in JIA

Researchers from Germany have studied a large cohort of juvenile idiopathic arthritis (JIA) patients and shown that JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.

Elder Rheumatoids Less Likely to Receive Biologics

Multiple studies have shown that elderly rheumatoid arthritis (RA) patients tend to be under-treated and receive DMARD therapies less often than younger RA patients. Now a VAMC study shows that the elderly are less likely to receive biologic agents yet are as likely to be subjected to glucocorticoid use.

Long-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis

Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in children with systemic onset juvenile idiopathic arthritis (sJIA). Now, long-term data from the extension studies from two phase III studies shows that canakinumab yields long-term improvements with reduced glucocorticoid dosing with no new safety findings with long-term use.

Defining Refractory Rheumatoid Arthritis

Researchers from the British Society for Rheumatology Biologics (BSRBR) set out to define under what circumstances will rheumatoid arthritis (RA) patients manifest biologic disease-modifying antirheumatic drugs (bDMARDs) refractory disease.

Using the patients from the BSRBR Register (2001 to 2014) they defined patients as bDMARD refractory when they initiated their third class of bDMARD.

Venous Thromboembolism Increased with Rheumatoid Arthritis, Not with TNF Inhibition

Venous thromboembolism (VTE) is a common adverse event throughout medicine and includes both pulmonary embolism (PE) and deep vein thrombosis (DVT).   The cost of diagnosing a thromboembolic event is approximately $4000 - $5550, while the annual cost of treating one case of VTE is between $17,000 and $19,000. The impact of VTE is substantial.